Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis.
Li YJ, Chen LR, Yang ZL, Wang P, Jiang FF, Guo Y, Qian K, Yang M, Yin SJ, He GH. Clin Rheumatol. 2022 Aug 29.
OAT10/SLC22A13 Acts as a Renal Urate Re-Absorber: Clinico-Genetic and Functional Analyses With Pharmacological Impacts.
Toyoda Y, Kawamura Y, Nakayama A, Morimoto K, Shimizu S, Tanahashi Y, Tamura T, Kondo T, Kato Y, Ichida K, Suzuki H, Shinomiya N, Kobayashi Y, Takada T, Matsuo H. Front Pharmacol. 2022 Apr 6;13:842717.
URAT1-selective inhibition ameliorates insulin resistance by attenuating diet-induced hepatic steatosis and brown adipose tissue whitening in mice.
Tanaka Y, Nagoshi T, Takahashi H, Oi Y, Yoshii A, Kimura H, Ito K, Kashiwagi Y, Tanaka TD, Yoshimura M. Mol Metab. 2022 Jan;55:101411.
Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.
Lee YH, Song GG. Int J Clin Pharmacol Ther. 2022 Mar;60(3):159-166.
Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials.
Takahashi T, Beppu T, Hidaka Y, Hosoya T. Clin Exp Hypertens. 2021 Nov 17;43(8):730-741.
Identification of Human UDP-Glucuronosyltransferase and Sulfotransferase as Responsible for the Metabolism of Dotinurad, a Novel Selective Urate Reabsorption Inhibitor.
Omura K, Motoki K, Kobashi S, Miyata K, Yamano K, Iwanaga T. Drug Metab Dispos. 2021 Nov;49(11):1016-1024.
Comparative study of a novel selective urate reabsorption inhibitor “dotinurad” among patient groups with different stages of renal dysfunction.
Takahashi T, Beppu T, Hidaka Y, Hosoya T. Clin Exp Nephrol. 2021 Dec;25(12):1336-1345.
Efficacy and Safety of Dotinurad in Hyperuricemic Patients With or Without Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Iqbal A, Iqbal K, Farid E, Ishaque A, Hasanain M, Bin Arif T, Arshad Ali S, Rathore SS, Malik M.Cureus. 2021 Apr 12;13(4):e14428.
Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout.
Ishikawa T, Takahashi T, Taniguchi T, Hosoya T.Expert Opin Pharmacother. 2021 Aug;22(11):1397-1406.
Hypouricemic agents reduce indoxyl sulfate excretion by inhibiting the renal transporters OAT1/3 and ABCG2.
Taniguchi T, Omura K, Motoki K, Sakai M, Chikamatsu N, Ashizawa N, Takada T, Iwanaga T.Sci Rep. 2021 Mar 31;11(1):7232.
Novel monocyclic amide-linked phenol derivatives without mitochondrial toxicity have potent uric acid-lowering activity.
Uda J, Kobashi S, Ashizawa N, Matsumoto K, Iwanaga T.Bioorg Med Chem Lett. 2021 May 15;40:127900.
Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity.
Uda J, Kobashi S, Miyata S, Ashizawa N, Matsumoto K, Iwanaga T.ACS Med Chem Lett. 2020 Jul 15;11(10):2017-2023.
Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor.
Omura K, Miyata K, Kobashi S, Ito A, Fushimi M, Uda J, Sasaki T, Iwanaga T, Ohashi T.Drug Metab Pharmacokinet. 2020 Jun;35(3):313-320.
A drug-drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult males.
Furihata K, Nagasawa K, Hagino A, Kumagai Y.Clin Exp Nephrol. 2020 Mar;24(Suppl 1):36-43.
A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients.
Hosoya T, Furuno K, Kanda S.Clin Exp Nephrol. 2020 Mar;24(Suppl 1):103-111.
Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study.
Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T.Clin Exp Nephrol. 2020 Mar;24(Suppl 1):62-70.
A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout.
Hosoya T, Furuno K, Kanda S.Clin Exp Nephrol. 2020 Mar;24(Suppl 1):71-79.
Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects.
Nakatani H, Fushimi M, Sasaki T, Okui D, Ohashi T.Clin Exp Nephrol. 2020 Mar;24(Suppl 1):8-16.
Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout.
Hosoya T, Fushimi M, Okui D, Sasaki T, Ohashi T.Clin Exp Nephrol. 2020 Mar;24(Suppl 1):80-91.
Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor.
Fukase H, Okui D, Sasaki T, Fushimi M, Ohashi T, Hosoya T.Clin Exp Nephrol. 2020 Mar;24(Suppl 1):17-24.
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.
Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T.Clin Exp Nephrol. 2020 Mar;24(Suppl 1):53-61.
Pharmacokinetic/pharmacodynamic modeling and simulation of dotinurad, a novel uricosuric agent, in healthy volunteers.
Motoki K, Igarashi T, Omura K, Nakatani H, Iwanaga T, Tamai I, Ohashi T.Pharmacol Res Perspect. 2019 Nov 26;7(6):e00533.
Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment.
Kumagai Y, Sakaki M, Furihata K, Ito T, Inoue K, Yoshida T, Matsumoto S, Furuno K, Hagino A.Clin Exp Nephrol. 2020 Mar;24(Suppl 1):25-35.
Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
Kuriyama S.Clin Exp Nephrol. 2020 Mar;24(Suppl 1):1-5.
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study.
Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T.Clin Exp Nephrol. 2020 Mar;24(Suppl 1):44-52.
The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor.
Okui D, Sasaki T, Fushimi M, Ohashi T.Clin Exp Nephrol. 2020 Mar;24(Suppl 1):92-102.
Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor.
Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, Chikamatsu N, Hagihara C, Hashiba M, Iwanaga T.J Pharmacol Exp Ther. 2019 Oct;371(1):162-170.
